Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
No abstract available

Keywords: COVID-19; antirheumatic agents; rituximab; vaccination.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Antirheumatic Agents / therapeutic use*
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / immunology*
  • COVID-19 Vaccines / therapeutic use
  • Female
  • Humans
  • Immunocompromised Host / immunology
  • Immunogenicity, Vaccine / drug effects*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rheumatic Diseases / drug therapy
  • Rheumatic Diseases / immunology
  • Rituximab / therapeutic use*
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Antirheumatic Agents
  • COVID-19 Vaccines
  • Rituximab